Neurocrine Biosciences Inc (NASDAQ: NBIX) has reported earnings for its third fiscal quarter (ending September 30) of $1.28 versus $0.85 for the same period a year ago — an increase of 51%. For the latest four quarters through September 30, E.P.S. were $3.87 versus $1.97 for the same period a year ago — an increase of 96%.
Recent Price Action
Neurocrine Biosciences Inc (NASDAQ: NBIX) stock enjoyed a very large increase of 7.0% on 10/30/24. The shares closed at $124.33. Moreover, exceptionally high trading volume at 262% of normal accompanied the advance. The stock has risen 6.5% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
NBIX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Neurocrine Biosciences has a current Value Trend Rating of C (Low Neutral). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Neurocrine Biosciences has a neutral Appreciation Score of 58 and a slightly negative Power Rating of 39, with the Low Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment